Bosch has soared 17% to Rs 11,500, also its record high on the BSE, on buzz that the parent company may hike stake in the company.
The stock has opened at Rs 9,850 and seen over two-fold jump in trading volumes. A combined 74,000 shares have already changed hands on the counter against an average less than 10,000 shares that were traded daily in past two weeks on the BSE and NSE.
Shares of multinational company (MNC) engaged in auto parts and equipment business has outperformed the market by gaining 30% in past six trading sessions against 2.2% rise in benchmark S&P BSE Sensex.
Robert Bosch Gmbh, the Germany-based parent company, held 71% stake in Bosch as on September 30, 2013.
Open offers from MNCs like Hindustan Unilever, GlaxoSmithKline Consumer and GlaxoSmithKline Pharmaceuticals in the last one year make investors optimistic.
Earlier this month, GlaxoSmithKline Plc (GSK) had made an open offer to increase its holding in GlaxoSmithKline Pharmaceuticals to up to 75% from 50.67% at offer price of Rs 3,100 per share.
In July this year, HUL hiked its stake by 14.8% to 67.25% , while in November 2012, GlaxoSmithKline Consumer announced an open offer to increase its stake from 43.2% to 72.46%, at Rs 3,900 per share.
The stock has opened at Rs 9,850 and seen over two-fold jump in trading volumes. A combined 74,000 shares have already changed hands on the counter against an average less than 10,000 shares that were traded daily in past two weeks on the BSE and NSE.
Shares of multinational company (MNC) engaged in auto parts and equipment business has outperformed the market by gaining 30% in past six trading sessions against 2.2% rise in benchmark S&P BSE Sensex.
Robert Bosch Gmbh, the Germany-based parent company, held 71% stake in Bosch as on September 30, 2013.
Open offers from MNCs like Hindustan Unilever, GlaxoSmithKline Consumer and GlaxoSmithKline Pharmaceuticals in the last one year make investors optimistic.
Earlier this month, GlaxoSmithKline Plc (GSK) had made an open offer to increase its holding in GlaxoSmithKline Pharmaceuticals to up to 75% from 50.67% at offer price of Rs 3,100 per share.
In July this year, HUL hiked its stake by 14.8% to 67.25% , while in November 2012, GlaxoSmithKline Consumer announced an open offer to increase its stake from 43.2% to 72.46%, at Rs 3,900 per share.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%